To a company that spent three years recovering from a crippling accounting scandal, Tysabri had looked like the ticket to its resurgence.
The Elan Corporation, which developed Tysabri with Biogen Idec, had looked to the drug, a multiple sclerosis treatment, to catapult it into the ranks of the world's top biotechnology companies. Since the drug's introduction in November, Tysabri had shown the patient response, and earnings potential, that would make it a blockbuster.
